One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!

Michael R. McDonnell net worth and biography

Michael McDonnell Biography and Net Worth

CFO of IQVIA

Michael McDonnell is the Executive Vice President and Chief Financial Officer of Biogen and has served on the Executive Committee since August 2020. Mr. McDonnell joined Biogen from IQVIA (formerly Quintiles) a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, where he was the company’s Executive Vice President and Chief Financial Officer since December 2015.

Prior to joining Biogen, Mr. McDonnell, served for seven years as CFO at Intelsat, a leading global satellite service provider. Before that, he was CFO at both MCG Capital Corporation and EchoStar Communications (DishNetwork). Earlier in his career, he was a partner at PricewaterhouseCoopers, LLP. Mike also served as a member of the board of directors of Catalyst Health Solutions, Inc., a publicly held pharmacy benefits management company from 2005 until 2012.

Mr. McDonnell has a Bachelor of Science degree in accounting from Georgetown University and is a certified public accountant.

What is Michael R. McDonnell's net worth?: The estimated net worth of Michael R. McDonnell is at least $3.38 million as of January 2nd, 2020. Mr. McDonnell owns 14,366 shares of IQVIA stock worth more than $3,382,906 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. McDonnell may own. Learn More about Michael R. McDonnell's net worth.
How do I contact Michael R. McDonnell?: The corporate mailing address for Mr. McDonnell and other IQVIA executives is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. IQVIA can also be reached via phone at (919) 998-2000 and via email at [email protected]. Learn More on Michael R. McDonnell's contact information.
Has Michael R. McDonnell been buying or selling shares of IQVIA?: Michael R. McDonnell has not been actively trading shares of IQVIA during the past quarter. Most recently, Michael R. Mcdonnell sold 12,000 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.07, for a transaction totalling $1,860,840.00. Following the completion of the sale, the chief financial officer now directly owns 14,366 shares of the company's stock, valued at $2,227,735.62. Learn More on Michael R. McDonnell's trading history.
Who are IQVIA's active insiders?: IQVIA's insider roster includes Ari Bousbib (Insider), Ronald Bruehlman (Insider), John Connaughton (Director), John Danhakl (Director), Kevin Knightly (Insider), Michael McDonnell (CFO), Ronald Rittenmeyer (Director), and Eric Sherbet (Insider). Learn More on IQVIA's active insiders.
Are insiders buying or selling shares of IQVIA?: In the last year, insiders at the medical research company sold shares 7 times. They sold a total of 87,540 shares worth more than $20,013,870.89. The most recent insider tranaction occured on March, 1st when insider Ari Bousbib sold 31,678 shares worth more than $7,936,289.34. Insiders at IQVIA own 1.6% of the company. Learn More about insider trades at IQVIA.
Information on this page was last updated on 3/1/2024.

Michael R. McDonnell Insider Trading History at IQVIA

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/2/2020	Sell	12,000	$155.07	$1,860,840.00	14,366
12/3/2018	Sell	9,500	$128.35	$1,219,325.00

Michael R. McDonnell Buying and Selling Activity at IQVIA

IQVIA Company Overview

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Today's Range

Now: $235.48

$233.10

$236.93

50 Day Range

MA: $245.35

$227.17

$259.15

2 Week Range

Now: $235.48

$167.42

$261.73

Volume

385,607 shs

Average Volume

965,942 shs

Market Capitalization

$42.74 billion

P/E Ratio

32.30

Dividend Yield

N/A

Beta

1.5

The World's First "$20 Trillion Drug?"

From Behind the Markets | Ad

Get the name of the stock here >>>